company background image
ACXP

Acurx Pharmaceuticals NasdaqCM:ACXP Stock Report

Last Price

US$3.45

Market Cap

US$40.0m

7D

13.9%

1Y

-23.8%

Updated

07 Dec, 2022

Data

Company Financials +
ACXP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ACXP Stock Overview

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Acurx Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acurx Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.45
52 Week HighUS$4.89
52 Week LowUS$2.33
Beta0
1 Month Change16.55%
3 Month Change-12.66%
1 Year Change-23.84%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.27%

Recent News & Updates

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Recent updates

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30
Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Shareholder Returns

ACXPUS BiotechsUS Market
7D13.9%1.9%-0.4%
1Y-23.8%-11.2%-20.6%

Return vs Industry: ACXP underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: ACXP underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is ACXP's price volatile compared to industry and market?
ACXP volatility
ACXP Average Weekly Movement10.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ACXP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ACXP's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20174Dave Lucihttps://www.acurxpharma.com

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.

Acurx Pharmaceuticals, Inc. Fundamentals Summary

How do Acurx Pharmaceuticals's earnings and revenue compare to its market cap?
ACXP fundamental statistics
Market CapUS$39.99m
Earnings (TTM)-US$11.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACXP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$11.46m
Earnings-US$11.46m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ACXP perform over the long term?

See historical performance and comparison